Published in J Virol on February 01, 2003
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol (2004) 1.81
Detection of G-quadruplex DNA in mammalian cells. Nucleic Acids Res (2013) 1.53
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol (2008) 1.26
Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J Virol (2004) 1.25
Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine (2006) 1.21
On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol (2009) 1.11
Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res (2008) 1.09
Does Japanese encephalitis virus share the same cellular receptor with other mosquito-borne flaviviruses on the C6/36 mosquito cells? Virol J (2007) 1.06
Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol (2009) 0.97
Isolation and genetic characteristics of human genotype 1 Japanese encephalitis virus, China, 2009. PLoS One (2011) 0.97
Twenty years of DENV-2 activity in Brazil: molecular characterization and phylogeny of strains isolated from 1990 to 2010. PLoS Negl Trop Dis (2013) 0.87
Structure of yellow fever virus envelope protein domain III. Virology (2009) 0.87
Characterization of the GXXXG motif in the first transmembrane segment of Japanese encephalitis virus precursor membrane (prM) protein. J Biomed Sci (2010) 0.86
Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice. Med Microbiol Immunol (2007) 0.85
NMR solution structure and backbone dynamics of domain III of the E protein of tick-borne Langat flavivirus suggests a potential site for molecular recognition. Protein Sci (2006) 0.85
Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J Virol (2004) 0.80
Envelope protein gene based molecular characterization of Japanese encephalitis virus clinical isolates from West Bengal, India: a comparative approach with respect to SA14-14-2 live attenuated vaccine strain. BMC Infect Dis (2013) 0.80
Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III. PLoS Negl Trop Dis (2015) 0.78
Production of Japanese Encephalitis Virus Antigens in Plants Using Bamboo Mosaic Virus-Based Vector. Front Microbiol (2017) 0.75
Thermodynamic mechanism for the evasion of antibody neutralization in flaviviruses. J Am Chem Soc (2014) 0.75
The Molecular Epidemiology and Evolution of Murray Valley Encephalitis Virus: Recent Emergence of Distinct Sub-lineages of the Dominant Genotype 1. PLoS Negl Trop Dis (2015) 0.75
Expression of domain III of the envelope protein from GP-78: a Japanese encephalitis virus. Virusdisease (2017) 0.75
The atomic structure of protein-protein recognition sites. J Mol Biol (1999) 12.63
The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 12.25
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Conformations of immunoglobulin hypervariable regions. Nature (1990) 5.31
Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology (1998) 3.80
Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity-determining region 3 residues in antigen interaction. J Biol Chem (1997) 2.25
Conformations of the third hypervariable region in the VH domain of immunoglobulins. J Mol Biol (1998) 1.96
Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology (1991) 1.85
Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology (1996) 1.74
Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology (1994) 1.67
Analysis of disulfides present in the membrane proteins of the West Nile flavivirus. Virology (1987) 1.63
Secondary structure of the 3'-noncoding region of flavivirus genomes: comparative analysis of base pairing probabilities. RNA (1997) 1.62
Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol (1989) 1.59
High resolution functional analysis of antibody-antigen interactions. J Mol Biol (1992) 1.49
Characterization of monoclonal antibody-escape mutants of tick-borne encephalitis virus with reduced neuroinvasiveness in mice. J Gen Virol (1997) 1.45
Electrostatic interactions control the parallel and antiparallel orientation of alpha-helical chains in two-stranded alpha-helical coiled-coils. Biochemistry (1994) 1.40
Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence. J Gen Virol (1993) 1.28
A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J Virol (1990) 1.19
Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res (1997) 1.16
Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain. J Gen Virol (1996) 1.15
Characterization of a disulphide bridge-stabilized antigenic domain of tick-borne encephalitis virus structural glycoprotein. J Gen Virol (1987) 1.10
Evaluation of mutagenesis for epitope mapping. Structure of an antibody-protein antigen complex. J Biol Chem (1993) 0.92
Binding of an antibody mimetic of the human low density lipoprotein receptor to apolipoprotein E is governed through electrostatic forces. Studies using site-directed mutagenesis and molecular modeling. J Biol Chem (2000) 0.91
Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system. Vaccine (1995) 0.86
Molecular and structural basis of the specificity of a neutralizing acetylcholine receptor-mimicking antibody, using combined mutational and molecular modeling analyses. J Biol Chem (2000) 0.85
Characterization of neutralizing anti-pre-S1 and anti-pre-S2 (HBV) monoclonal antibodies and their fragments. Mol Immunol (1999) 0.82
Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein. J Biol Chem (2003) 2.09
Is avian influenza A (H7N9) virus staggering its way to humans? J Formos Med Assoc (2013) 1.52
Review of dengue virus and the development of a vaccine. Biotechnol Adv (2010) 1.35
High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine (2006) 1.24
Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS One (2011) 1.10
Production of EV71 vaccine candidates. Hum Vaccin Immunother (2012) 1.05
Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine (2008) 0.99
Dendritic cell activation by recombinant hemagglutinin proteins of H1N1 and H5N1 influenza A viruses. J Virol (2010) 0.94
Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol (2012) 0.91
Characterization of the GXXXG motif in the first transmembrane segment of Japanese encephalitis virus precursor membrane (prM) protein. J Biomed Sci (2010) 0.86
Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS One (2011) 0.86
Detection of swine-origin influenza A (H1N1) viruses using a localized surface plasmon coupled fluorescence fiber-optic biosensor. Biosens Bioelectron (2010) 0.85
Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One (2012) 0.84
Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine (2011) 0.81
Different immunity elicited by recombinant H5N1 hemagglutinin proteins containing pauci-mannose, high-mannose, or complex type N-glycans. PLoS One (2013) 0.81
Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in mice. PLoS One (2011) 0.81
High genetic stability of dengue virus propagated in MRC-5 cells as compared to the virus propagated in vero cells. PLoS One (2008) 0.80
Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses. Biotechnol J (2013) 0.79
Mosquito and mammalian cells grown on microcarriers for four-serotype dengue virus production: variations in virus titer, plaque morphology, and replication rate. Biotechnol Bioeng (2004) 0.79
Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV. Hum Vaccin Immunother (2013) 0.78
Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development. Vaccine (2005) 0.78
Identification of a heparin binding peptide from the Japanese encephalitis virus envelope protein. Biopolymers (2010) 0.77
A novel RNA silencing vector to improve antigen expression and stability in Chinese hamster ovary cells. Vaccine (2007) 0.77
Generating stable Chinese hamster ovary cell clones to produce a truncated SARS-CoV spike protein for vaccine development. Biotechnol Prog (2010) 0.76
Identification of mimotopes of the Japanese encephalitis virus envelope protein using phage-displayed combinatorial peptide library. J Mol Microbiol Biotechnol (2004) 0.75
Construction and characterization of insect cell-derived influenza VLP: cell binding, fusion, and EGFP incorporation. J Biomed Biotechnol (2010) 0.75
A novel E1B-55kD-deleted oncolytic adenovirus carrying mutant KRAS-regulated hdm2 transgene exerts specific antitumor efficacy on colorectal cancer cells. Mol Cancer Ther (2010) 0.75
Enhanced antibody affinity to Japanese encephalitis virus E protein by phage display. Biochem Biophys Res Commun (2007) 0.75
An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells. Biochem Biophys Res Commun (2004) 0.75
Using recombinant DNA technology for the development of live-attenuated dengue vaccines. Enzyme Microb Technol (2012) 0.75
Zika Virus Molecular Biology and Perspectives for Vaccine Development: A Review. J Nurs Res (2017) 0.75